This week, the UCLA Vine Street Clinic (UVSC) team hosted site visitors from the HIV Prevention Trials Network (HPTN). UVSC is one of 21 sites participating in the HPTN 085 trial, also known as the AMP (Antibody Mediated Prevention) study. This study will evaluate the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in healthy adults at high risk of HIV infection. Participants will be men who have sex with men (MSM) and transgender individuals, who will receive an IV infusion of the antibody or a placebo every 8 weeks for approximately two years.
